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Abstract
Background: Cardiovascular progenitor cells (CPCs) have been identified within the developing mouse heart and
differentiating pluripotent stem cells by intracellular transcription factors Nkx2.5 and Islet 1 (Isl1). Study of endogenous and
induced pluripotent stem cell (iPSC)-derived CPCs has been limited due to the lack of specific cell surface markers to isolate
them and conditions for their in vitro expansion that maintain their multipotency.
Methodology/Principal Findings: We sought to identify specific cell surface markers that label endogenous embryonic
CPCs and validated these markers in iPSC-derived Isl1+/Nkx2.5+ CPCs. We developed conditions that allow propagation and
characterization of endogenous and iPSC-derived Isl1+/Nkx2.5+ CPCs and protocols for their clonal expansion in vitro and
transplantation in vivo. Transcriptome analysis of CPCs from differentiating mouse embryonic stem cells identified a panel of
surface markers. Comparison of these markers as well as previously described surface markers revealed the combination of
Flt1+/Flt4+ best identified and facilitated enrichment for Isl1+/Nkx2.5+ CPCs from embryonic hearts and differentiating iPSCs.
Endogenous mouse and iPSC-derived Flt1+/Flt4+ CPCs differentiated into all three cardiovascular lineages in vitro. Flt1+/Flt4+
CPCs transplanted into left ventricles demonstrated robust engraftment and differentiation into mature cardiomyocytes
(CMs).
Conclusion/Significance: The cell surface marker combination of Flt1 and Flt4 specifically identify and enrich for an
endogenous and iPSC-derived Isl1+/Nkx2.5+ CPC with trilineage cardiovascular potential in vitro and robust ability for
engraftment and differentiation into morphologically and electrophysiologically mature adult CMs in vivo post
transplantation into adult hearts.
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Introduction
Despite therapeutic advancements, cardiovascular disease
remains a major cause of morbidity and mortality worldwide.
Although current therapies slow the progression of cardiovascular
disease, there are few if any options to reverse or repair damaged
myocardium. Unfortunately, adult cardiac myocytes (CMs) lack
the ability to divide and replace those that are damaged after
injury in any clinically significant manner [1]. Investigators have
been exploring the feasibility of directly injecting stem cells into the
heart for therapeutic cell transplantation and regeneration. While
multiple animal studies have demonstrated the ability of adult stem
cells to improve left ventricular function, long-lasting effects, CM
differentiation or even engraftment of injected cells has been more
difficult to establish [2,3]. Likewise, early human clinical trials
testing the efficacy of adult stem cell therapy to restore perfusion
and mechanical function to the heart after myocardial infarction
(MI), although promising, have had variable results [4]. Since most
preclinical studies have demonstrated very low rates of cardiac
differentiation when using these cells [5], there is increasing
consensus that transplanted adult stem cells may have a limited
capacity for true cardiac regeneration and their beneficial effects
are more likely related to paracrine mechanisms [6]. This
highlights the need for cell types that can provide long-lasting
engraftment and myogenesis either alone or in combination with
existing cell types. Embryonic stem cells (ESCs) are a reliable
source of authentic CMs, but issues of immunogenicity, oncogenic
risk and ethical concerns have hampered their clinical translation.
Recent advances in stem cell biology to induce pluripotency in
somatic cells make the potential of autologous, regenerative
strategies a viable possibility [7]. However, translating the promise
of iPSCs into a viable therapy will require the identification and
characterization of appropriate iPSC-derived progenitor cells. We
believe that the optimal cell type would be lineage-committed,
multipotent CPCs that satisfy the need for multilineage differen-
tiation while limiting the oncogenic risk of injecting undifferenti-
ated iPSCs or ESCs.
Recently, a multipotent CPC was identified based on the
expression of transcription factors Isl1+ and Nkx2.5+ [8,9] in
ESCs and fetal hearts; however, surface markers to identify and
enrich for these Isl1+/Nkx2.5+ CPCs are neither specific nor
uniformly agreed upon. Previously described cell surface
proteins Flk1 and Kit oncogene (c-kit), which have been used
in combination to identify mouse CPCs, are not specific
markers for endogenous CPCs [10] since Flk1 is broadly
expressed developmentally on all cardiovascular cell types and
not limited to Isl1+/Nkx2.5+ CPCs [11]. Genetically modifying
CPCs with integrating viruses to express fluorescent markers
under the control of Isl1 or Nkx2.5 promoters has also been
used to identify these CPCs [12]. However, this would
complicate their use clinically in human trials due to potential
oncogenic risk incurred by genomic manipulation. Therefore,
the ability to utilize CPCs derived from human iPSCs
therapeutically will require the identification of surface markers
to isolate and enrich for Isl1+/Nkx2.5+ CPCs without genetic
manipulation [10]. Furthermore, it has proven difficult to
propagate and expand progenitor cells while simultaneously
maintaining their multipotent differentiation potential, hamper-
ing attempts to generate sufficient numbers of CPCs ex vivo to
study and/or use in regenerative therapies. Thus, the lack of
specific cell surface markers that identify Isl1+/Nkx2.5+ CPCs in
an unmodified form and the lack of appropriate conditions to
expand them in vitro remains one of the major roadblocks facing
translational clinical applications of CPCs [10].
In this study, we attempted to identify cell surface markers that
are specific to and allow enrichment of Isl1+/Nkx2.5+ CPCs. We
identified Flt1 and Flt4 as a novel cell surface marker combination
that is specific to and enriches for mouse endogenous and iPSC-
derived CPCs. These Flt1+/Flt4+ CPCs have trilineage cardiovas-
cular potential and can be expanded ex vivo, feeder-free, using
small molecule inhibitors. These Flt1+/Flt4+ CPCs not only have
the ability to be clonally expanded and differentiate into all three
cardiovascular lineages in vitro, their in vivo differentiation potential
post-transplantation appears to be preferentially towards authentic
adult CMs both morphologically and electrophysiologically. Thus,
utilizing the approaches outlined in this report, the combination of
surface markers Flt1 and Flt4 enrich for iPSC-derived CPCs,
which could be a unique source of multipotent progenitor cells for
cardiac cell therapy.
Materials and Methods
All surgeries were performed under the supervision and with
approval of the University of California, Los Angeles Animal
Review Committee.
Microarray Analysis for Identification of CPC Surface
Markers
RNA samples from mouse ESCs or ESC-derived Flk1+ cells
were analyzed using Illumina Microarrays and have been
previously reported [13]. Briefly, biotinylated cRNA was prepared
using the Illumina RNA Amplification Kit (Ambion). Samples
were used for hybridization on a Sentrix MouseRef-8 Expression
BeadChip System (Illumina). The microarray raw data was
analyzed using BeadStudio 3.2.2 (Illumina). For additional details,
see the online supplementary methods (Methods S1).
Immunohistochemistry of Endogenous CPCs
Immunofluorescent staining (antibodies listed in Table S1) of
paraffin-embedded tissue sections of E15.5 mouse embryonic
hearts was performed as previously described [13]. Fluorescence
images were acquired using a confocal TCS SP2 AOBS laser-
scanning microscope system (Leica). Images were processed with
Adobe Photoshop CS3 (Adobe). Additional details are available in
the online supplementary methods (Methods S1).
Isolation and Expansion of Endogenous CPCs
Mouse hearts were dissected from E15.5 embryos (CF1-mice;
Charles River). To harvest CPCs, heart tissue was minced and
subjected to collagenase digestion. Murine cells were maintained
on Mitomycin-C treated, primary mouse embryonic fibroblasts
(MEF) in IQ1-supplemented medium [14]. Cells were expanded
for 8 days and the Flt1+/Flt4+ cells isolated by indirect magnetic-
activated cell sorting (MACS) (Stem Cell Technologies) or
fluorescence-activated cell sorting (FACS) using conjugated Flt1
and Flt4 antibodies (Abcam). For more details, see the online
supplementary methods (Methods S1).
Isolation of iPSC-derived CPCs
Murine iPSCs were generated from C57/BL6 mice as
previously described [13], transduced to constitutively express
green fluorescent protein (GFP), and expanded on Mitomycin C
inactivated MEFs and maintained in an undifferentiated state in
LIF medium. Mouse iPSCs were differentiated on Collagen IV
coated plates for 4 days and dissociated into single cell suspension
with 0.05% trypsin (Invitrogen). Flt1+/Flt4+ cells were isolated by
indirect MACS or FACS using conjugated Flt1 and Flt4
Cardiovascular Progenitor Stem Cells
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antibodies (Abcam). For more details, see the online supplemen-
tary methods (Methods S1).
Differentiation Assays
For in vitro differentiation assays, purified Flt1+/Flt4+ cells were
plated on fibronectin-coated culture slides (BD Bioscience) in
either alpha-MEM (cardiac differentiation), PDGF medium
(smooth muscle differentiation), or VEGF medium (endothelial
differentiation) as previously described [13]. For additional details,
see the online supplementary methods (Methods S1).
Gene Expression Analysis
Total RNA was extracted from mouse hearts, mouse ESCs, the
Flt12/Flt42 negative cell fraction, as well as from mouse
undifferentiated and differentiated Flt1+/Flt4+ cells. Semi-quanti-
tative PCR was performed as previously described [13]. All mouse
primer sequences have been previously published [13]. Primer sets
specific for mouse Flt1 and Flt4 were purchased from R&D
Systems. For additional details, see the online supplementary
methods (Methods S1).
Clonal Expansion and Differentiation of CPCs
Skin fibroblasts from C57/BL6 mice were reprogrammed as
described [13] and stably transfected with a constitutively
expressed GFP. Single cell FACS sorting was performed for the
Flt1+/Flt4+ population on the ARIA-II Flow Cytometer. After cell
recovery overnight, Flt1+/Flt4+ cells were propagated feeder-free
in ESGRO media (Millipore), which was supplemented with IQ-1
(Calbiochem) and ROCK inhibitor Thiazovivin (Stemgent) on
fibronectin-coated plates (BD Bioscience). After four weeks,
colonies arising from single cell clones were dissociated and
replated onto fibronectin-coated culture slides (BD Bioscience) in
differentiation media for fourteen days as described before [13].
For additional details, see the online supplementary methods
(Methods S1).
In vivo Transplantation of Cardiac Progenitor Cells
GFP+ mouse iPSCs were differentiated and GFP+ Flt1+/Flt4+
CPCs were isolated by FACS sorting as described above. Post-sort,
Flt1+/Flt4+ CPCs were recovered overnight at 4uC in CPC pro-
survival media [15] prepared with ESGRO media (Millipore) and
pro-survival factors with growth factor–reduced Matrigel (BD
bioscience), supplemented with 100 mM ZVAD (Calbiochem),
50 nM Bcl-XL BH4 (Calbiochem), Cyclosporine A 200 nM (Wako
Pure Chemicals), 100 ng/ml IGF-1 (Peprotech), and 50 mM
pinacidil (Sigma). Flt1+/Flt4+ CPCs were recovered overnight in
CPC pro-survival at 4uC. Cells were then suspended at a
concentration of 50,000 cells per 50 ml of CPC pro-survival media
and injected into the anterior wall of the left ventricle at 10 ml per
injection site for a total of 5 injections. Sham injections with pro-
survival media were performed on control mice. 28 days post
injection, the animals were sacrificed, hearts were harvested, fixed
according to standard protocols and immunofluorescence imaging
was performed. For additional details, see the online supplemen-
tary methods (Methods S1).
Isolation and Electrophysiological Assessment of GFP+
Flt1+/Flt4+-derived CMs Post in vivo Transplant of CPCs
Adult mice were injected with 800 ml of heparin (5,000 units/
ml) intraperitonealy twenty minutes prior to harvesting of hearts.
Animals were anesthetized with isoflurane and hearts excised via a
thoracotomy. Single ventricular myocytes were enzymatically
separated using collagenase (3 mg/ml, Type II collagenase; Gibco
BRL) and protease (0.3 mg/ml, Type XIV protease; Sigma-
Aldrich). Following isolation, dissociated cells were washed three
times and resuspended at room temperature in modified Tyrode’s
solution, containing (in mmol/L): 136 NaCl, 5.4 KCl, 10 HEPES,
1.0 MgCl2, 0.33 NaH2PO4, 0.5 CaCl2, 10 glucose (pH 7.4).
Isolated CMs were loaded with 2 mM rhod-2AM and 1 ml
Pluronic F-127 (both from Molecular Probes). Cells were then
placed in an experimental chamber (0.5 ml) filled with normal
Tyrode’s solution. A Leica SP5 resonant LSCM system (Leica) was
used for confocal imaging. Cells were whole cell patch-clamped
and action potentials were induced at a rate of 0.2 Hz using the
current clamp mode of an Axopatch900A amplifier (Molecular
Devices, Sunnyvale, CA). Calcium transients were simultaneously
recorded. For additional details, see the online supplementary
methods (Methods S1).
Statistical Analysis
All data were presented as mean 6 standard error of the mean
(SEM). Statistical significance was assessed by Student’s t test or
ANOVA with Tukey’s multiple comparison test. P-values less than
0.05 were defined as statistically significant.
Results
The Flt1+/Flt4+ Cell Population in Developing Hearts is
Enriched for Isl1+/Nkx2.5+ Cardiac Progenitors
Cardiovascular progenitors that contribute to all three cardio-
vascular lineages identified by the transcription factor Isl1 have
been described in the developing human and mouse fetal heart
[16]. Although Flk1 has been widely accepted as a cell surface
marker to identify CPCs, at least in differentiating pluripotent stem
cells [17], it is not specific in vivo. Flk1 is a marker of early
cardiogenesis and, consistent with genetic tracking studies [11],
embryonic hearts express Flk1 diffusely making it a poor marker to
selectively identify and isolate endogenous CPCs (Fig. 1A). FACS
analysis demonstrated that Flk1 is also a nonspecific marker for
ESC-derived Isl1+/Nkx2.5+ CPCs as it labeled a heterogeneous
population of cells in differentiating mouse ESCs (Fig. 1B). Less
than 10% of Isl1+ cells were Flk1+ and less than 5% of Nkx2.5+
cells were Flk1+ (Fig. 1C, 1D). c-kit (CD117), another proposed
CPC marker, was equally nonspecific. Although Sca1 was able to
identify the greatest percentage of Isl1 or Nkx2.5 cells, it still only
captured a minority of these populations and is not expressed on
human cells.
To identify surface markers that could be used to specifically
label and enrich for CPCs, we first examined the transcriptome of
mouse ESC-derived Flk1+ cells, which includes a subpopulation of
cardiovascular progenitor cells, which have been shown to label a
trilineage CPC from differentiating embryonic stem cells [13].
Reanalysis of this microarray data identified six additional cell
surface markers that have been associated with various stem or
progenitor cell populations. In addition to Flk1, the two other
members of the vascular endothelial growth factor receptor
(VEGFR) family, VEGFR1 and VEGFR3 (Flt1 and Flt4) were
identified. To compare the utility of these cell surface markers in
identifying and enriching for the Isl1+ population, we performed a
detailed FACS analysis of cells dissociated from E15.5 mouse
embryonic hearts (Table 1). We examined the sensitivity and
specificity of Flt1, Flt4, Flk1, c-kit, CD31 (PECAM-1 or Platelet
Endothelial Cell Adhesion Molecule), CD34, and PDGFR-a
singly or in combination to identify and enrich for endogenous
Isl1+ putative CPCs. No cell surface marker was sufficient by itself
to identify the Isl1+ population (Table 1). When different
combinations of surface markers were compared, the combination
Cardiovascular Progenitor Stem Cells
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of Flt1/Flt4 was the most specific for identifying and enriching for
the Isl1+ population, as 89.4% of Flt1+/Flt4+ cells were Isl1+
(Table 1). Furthermore, Flt1+/Flt4+ identified 64.5% of the Isl1high
population, which we believe represents the true undifferentiated
CPC population [16] as Isl1 expression decreases as CPCs
differentiate into progeny cells. In contrast, only 7.43% of Flk1+
cells were Isl1+ and the combination of Flk1 and PDGFR-a, which
has been previously described to isolate cardiac progenitors from
differentiating ESCs [16], only identified 23.8% of the Isl1high
CPC population. As well, endogenous Isl1+ progenitors were
negative for SSEA-1, which has been reported to enrich for
primate ESC-derived Isl1+ cells [18]. To validate the expression of
these cell surface markers on putative CPCs, we immunostained
E15.5 mouse hearts for Isl1 and all three VEGF receptor family
members Flk1, Flt1 and Flt4. Flt1 and Flt4 expression preferen-
tially co-localized with Isl1+ cells (Fig. 2Aa–f). Although neither
Flt1 nor Flt4 are exclusively expressed on Isl1+ cells, their co-
expression reliably and specifically identified Isl1+ cells in the
developing mouse heart allowing for identification of the
endogenous Isl1+ population by FACS (Fig. 2B).
We performed immunostaining of E15.5 mouse hearts for Isl1
and for the pan-neuronal marker Microtubule-associated protein-2
(Map2) and the peripheral ganglion protein Neurofilament, Heavy
Polypeptide (NEFH)(Figure S1). Some Isl1+ cells were positive for
Map2, indicating their potential neural crest lineage, but fewer were
positive for NEFH. This is in line with recent reports that Isl1+ cells
in the heart, later in gestation, represent cells from the second heart
field, cardiac neural crest as well as cardiac ganglia.
Figure 1. Flk1 is not a specific marker for endogenous and mouse ESC-derived Isl1+ CPCs. (A) Immunohistochemical staining of E15.5
mouse heart identifies Isl1-expressing CPCs (blue) located in niches in outflow tracts. (B) FACS analysis of mouse ESC-derived Flk1+ cells reveals a
heterogeneous Flk1+ population with low enrichment for Isl1 (light blue bar) and Nkx2.5 (orange bar) cells (n = 3). (C & D) FACS analysis of
differentiated mouse ESCs reveals that Flk1 represents ,10% of Isl1+ cells (C; n = 3) and ,5% of Nkx2.5+ cells (D; n = 3).
doi:10.1371/journal.pone.0045603.g001
Cardiovascular Progenitor Stem Cells
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Isolated Endogenous Flt1+/Flt4+ Cells Expanded in vitro
Display Trilineage Differentiation Potential
To confirm that the Flt1+/Flt4+ population we identified were
indeed CPCs, we assessed their ability to differentiate into the
three cardiovascular lineages. Endogenous mouse Flt1+/Flt4+ cells
were isolated and expanded in vitro and then exposed to specific
differentiation conditions. The undifferentiated Flt1+/Flt4+ popu-
lation expressed high levels of progenitor cell markers including
Isl1, Nkx2.5, Flk1, Flt1, Flt4 and c-kit, but not genes associated
with differentiated cardiovascular cells (Fig. 3A). Differentiated
Flt1+/Flt4+ cells down-regulated these CPC markers and up-
regulated genes expressed in endothelial cells (EC) and smooth
muscle cells (SMC) as well as CMs (Fig. 3B, 3C and 3D). Thus, the
Flt1/Flt4 cell surface marker combination identifies a progenitor
population in developing mouse hearts that is able to differentiate
into all three cardiovascular cell types.
To quantify the in vitro differentiation potential of Flt1+/Flt4+
CPCs when compared to the cell population enriched for by the
marker Flk1, we isolated mouse ESC-derived Flt1+/Flt4+ and Flk1+
cells and compared them directly. Both cell populations were plated
in equal numbers onto fibronectin-coated plates post-FACS sorting
and exposed to identical CM differentiation conditions for 14 days.
7364.8% of the cells from differentiated Flt1+/Flt4+ CPCs were
Troponin C (TropC) positive compared to only 4365.7% of the
Flk1+ population. Furthermore, to assess the ability of Flt1 and Flt4
to capture the majority of the CPC population from differentiating
ESCs, the negative fraction population of Flt12/Flt42 cells was
collected and exposed to the same differentiation conditions.
Flt12/Flt42 cells had no cardiogenic differentiation potential when
exposed to identical differentiation conditions. The combination of
Flt1/Flt4 cell surface markers functionally enriches for a progenitor
cell population capable of a more robust in vitro CM differentiation
when compared to the cell population identified by the previously
described marker Flk1.
Single Flt1+/Flt4+ Cells are Authentic, Multipotent Cardiac
Progenitor Cells that can be Clonally Expanded and
Differentiated
To determine the clonal potential of Flt1+/Flt4+ cells, we
performed single cell FACS sorting of mouse iPSC-derived Flt1+/
Flt4+ cells onto fibronectin-coated plates. Post-FACS, these cells
were clonally expanded in the presence of IQ-1, a selective b-
catenin/p300 inhibitor [14,19] and Thiazovivn, a ROCK
inhibitor [20]. After plating Flt1+/Flt4+ cells at one cell per well,
54.2% (26 of 48) cells survived and formed colonies. After four
weeks, homogeneous clusters of cells (Fig. 4Aa–c), of which .90%
remained Flt1+/Flt4+ (Fig. 4B) were apparent. Post expansion,
colonies were dissociated and replated onto fibronectin-coated
plates and exposed to differentiation conditions as described
above. Spontaneously beating colonies were observed 13 days post
differentiation (Movie S1). Immunostaining of six independent
clones chosen randomly from colonies formed revealed that they
were all capable of forming spontaneously beating colonies and
differentiating into CMs (Fig. 4Ad, Figure S2), SMCs (Fig. 4Ae)
and ECs (Fig. 4Af). Thus, iPSC-derived Isl1+/Flt1+/Flt4+ cells can
be clonally expanded for a minimum of thirty days while
maintaining their surface marker phenotype and trilineage
differentiation potential.
In vivo Transplantation and Engraftment of Flt1+/Flt4+
CPCs
One limitation of many cell types used for cardiac cell therapy is
their limited capacity for engraftment and differentiation to mature
CMs. To assess the ability of Flt1+/Flt4+ CPCs to engraft and
differentiate in vivo, we isolated Flt1+/Flt4+ CPCs from GFP+ mouse
iPSCs and transplanted them into normal hearts of strain-matched
mice. iPSC-derived GFP+ Flt1+/Flt4+ CPCs were suspended in a
pro-survival media and injected into the anterior wall of the left
ventricle of adult mice. Examination of the transplanted myocardi-
um after 28 days revealed robust engraftment and differentiation of
GFP+ Flt1+/Flt4+ CPCs into Troponin C-expressing mature CMs
(Fig. 5A and 5B) and a-smooth muscle actin-expressing SMCs
(Fig. 5C). In contrast to the in vitro studies, we were not able to detect
differentiation into ECs. Histological assessment for an immune
reaction against injected CPCs revealed no evidence of infiltration of
CD45+ lymphocytes into the transplanted region (Figure S3).
Digestion and single cell analysis of the GFP+ Flt1+/Flt4+ CPC-
transplanted hearts revealed mature, adult-appearing GFP+ CMs
(Fig. 6A, 6B and 6C). Since many of the GFP+ CMs were
mononucleated this could not be explained by fusion of transplanted
CPCs with existing CMs (Fig. 6C). FACS analysis of single cell
Table 1. FACS analysis of cells dissociated from E15.5 mouse hearts.
Cell surface marker/s
% surface marker/s- labeled
cells that are Isl1+
% Isl1high cells labeled by
surface marker/s
% cells in E15.5 heart labeled
by surface marker/s
Flt1+ 19.7% 69.7% 7.6%
Flt4+ 19.4% 79.7% 15.9%
Flk1+ 7.43% 56.9% 27.2%
c-kit+ ,1% N/A 0.7%
CD31+ 5.4% 71.6% 49.8%
CD34+ 6.8% 87.6% 42.9%
Flk1+/PDGR-a+ 12.1% 23.8% 2.1%
Flt1+/Flt4+ 89.4% 64.5% 5.89%
Flk1+/Flt4+ 8.55% 70.6% 10.3%
Flt1+/CD31+ 19.4% 63.2% 9.58%
Flt4+/CD31+ 11.4% 49.8% 12.4%
FACS analysis of E15.5 mouse embryonic hearts for different cell surface marker/s identified by microarray analysis of mouse ESC-derived Flk1+ cells. Flt1/Flt4
combination is the most specific to identify and enrich for Isl1+ cells in the E15.5 heart.
doi:10.1371/journal.pone.0045603.t001
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suspensions demonstrated that,6% of the total cell population were
GFP+/Troponin I+ representing CMs derived from the transplanted
CPCs (Fig. 6D). To confirm that the GFP+ Flt1+/Flt4+-derived CMs
were also electrophysiologically mature, we loaded them with the
calcium indicator rhod-2 AM. GFP+ CMs (Fig. 6G) could be
externally paced at frequencies of 0.2 Hz to generate characteristic
action potentials (Fig. 6E), Ca2+ transients and cell shortening
indicative of electrically functional CMs (Fig. 6F, 6H, 6I). The
synchronous onset and rapid upstroke of the Ca2+ transient indicate
electrically triggered Ca2+ release typical of adult CMs (Fig. 6F).
Thus, iPSC-derived CPCs have the potential to engraft into the adult
myocardium and robustly differentiate into CMs with phenotypic
and electrophysiologic characteristics of adult CMs.
Discussion
To realize the true potential of cardiovascular regenerative
therapy, it will be necessary to identify a source of cardiac
progenitor cells that can be easily isolated from a renewable source
Figure 2. Novel surface marker combination Flt1 and Flt4 specifically label endogenous Isl1+ CPCs in E15.5 mouse hearts. (Aa-c)
Immunofluorescence imaging of E15.5 mouse fetal hearts shows that surface markers Flt1 (green) and Flt4 (blue) co-label Isl1+ CPCs (red) in
specialized niches. (Ad-f) Flt1+ (green) and Flt4+ (blue) double positive cells are also Flk1+ (red). (B) FACS analysis of digested E15.5 mouse hearts:
Flk1+/Flt1+/Flt4+ are greater than 90% Isl1+ confirming Flt1 and Flt4 in combination enrich for Isl1+ CPCs.
doi:10.1371/journal.pone.0045603.g002
Cardiovascular Progenitor Stem Cells
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without immunologic or oncogenic concerns. Multipotent CPCs
derived from differentiating iPSCs based on well-defined surface
markers and differentiation conditions would potentially address
this gap in cardiac cell therapy. Unlike the hematopoietic system
where the hierarchy of differentiation of progenitors is clearly
delineated and the surface markers well-defined [21], there is no
universally agreed upon developmental hierarchy for cardiovas-
cular progenitors as defined by surface markers. Multiple groups
have described different progenitors with lineage tracing and gene-
targeting studies as well as FACS analysis, all based on intracellular
Figure 3. Endogenous Flt1+/Flt4+ cells are multipotent CPCs that differentiate into all three lineages of the cardiovascular system.
(A) Semi-quantitative PCR analysis shows that undifferentiated murine Flt1+/Flt4+ cells express markers of mesodermal and cardiovascular progenitor
cells that are down-regulated during differentiation. (B–D) Differentiating murine Flt1+/Flt4+ cells show up-regulation of genes characteristic of the (B)
endothelial, (C) smooth muscle and (D) cardiac lineages.
doi:10.1371/journal.pone.0045603.g003
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transcription factors [22,23,24]. To date, studies identifying cell
surface markers for CPCs have been based mostly on ESC studies
evaluating different cell surface markers and their enrichment for
CPC transcription factors such as Nkx2.5 [25] and Isl1 [20]. This
study is the first to our knowledge to identify and functionally
validate specific cell surface markers for endogenous multipotent
Isl1+/Nkx2.5+ CPCs and to recapitulate this CPC in differentiating
iPSCs. The novel surface marker combination of Flt1 and Flt4 was
identified by our microarray analysis of the heterogeneous, ESC-
derived Flk1+ cell population [13]. These markers identify and
enrich for a true CPC and are more specific than other cell surface
marker combinations that have been described to identify
endogenous Isl1+ CPCs in the embryonic heart as demonstrated
by our FACS analysis (Table 1). It is very likely, given the hierarchy
that has been proposed in cardiovascular cell development, that
cardiovascular progenitors will express a unique cell surface
phenotype as they develop and enrich to varying extents for CPCs
[18,25,26]. When isolated, Flt1+/Flt4+ CPCs from both endoge-
nous and iPSC sources expressed the cardiogenic transcription
factors Isl1 [23] and Nkx2.5 [25] and were capable of differentiating
into all three cardiovascular cell types. Furthermore, Flt1+/Flt4+
CPCs demonstrated more robust in vitro differentiation into CMs
compared to Flk1+ cells. Not surprisingly, the more robust
differentiation potential of Flt1+/Flt4+ CPCs to CMs as compared
to Flk1+ cells is likely due to the fact that the Flt1+/Flt4+ cell
population represents a more homogeneous CPC population
compared to the heterogeneous population identified by Flk1.
Moreover, the iPSC-derived Flt12/Flt42 cells showed no in vitro
differentiation potential into CMs, confirming that the combination
of Flt1+/Flt4+ enriched for the majority of CPCs from differenti-
ating iPSCs.
Although not a cardiac-specific marker, Isl1 has been identified
by many groups to developmentally label cardiovascular progen-
itors at early post-gastrulation stages of mouse development that
will give rise to the second heart field, which is primarily
responsible for generating the right ventricle (RV), atria and
outflow tracts, and to partially contribute to the formation of the
conduction system [22,23]. Additionally, intersectional fate
mapping has determined that in the embryonic heart, Isl1+ cells
label, along with the second heart field forming cells, cells derived
from the cardiac neural crest and the cardiac ganglia [27,28,29].
Furthermore, Weinberger et al. demonstrated in the adult murine
heart between 1 month and 18 months that Isl1 labels cells of the
sino-atrium; however, there was no evidence of Isl1+ cells post
infarct [30]. Our attempts to identify Isl1+ cells in the adult
myocardium by flow cytometry and immunofluorescence have
been unsuccessful. Our staining of embryonic hearts identified two
subpopulations of Isl1+ cells based on their expression of
neurological markers: those positive for both neuronal marker
Map2 and the peripheral ganglia marker NEFH, and those
positive only for Map2. We believe these Map2+ cells represent
neural crest-derived Isl1+ cells which, along with those found
earlier in development, can act as CPCs in agreement with recent
work [31,32].
The use of Isl1 as a marker to identify progenitors for cell
transplantation has been criticized because it theoretically identifies
a CPC that will give rise to a right ventricular CM, which might not
function physiologically the same as a left ventricular CM.
However, there is little evidence to support this assertion and these
same endogenous Isl1+ progenitors also contribute to the left
ventricle [8,26,33]. Additionally, an Isl1+ epicardial cardiac
progenitor has been identified that generates CMs in the LV [34].
We demonstrate that iPSC-derived Flt1+/Flt4+ CPCs, when
transplanted into the LV of strain-matched mice, engraft and
preferentially differentiate into CMs that morphologically and
electrophysiologically resemble adult left ventricular CMs (Fig. 6).
Functionally, these Flt1+/Flt4+ CPCs demonstrate a robust in vitro
and in vivo cardiovascular differentiation potential, which is the main
aim of this study to identify specific surface markers to isolate iPSC-
derived CPCs for potential regenerative therapies.
Although, Flt1+/Flt4+ CPCs demonstrated a clonal trilineage
differentiation potential in vitro, we were able to detect potent
cardiac differentiation in vivo as well as smooth muscle differenti-
ation, but no demonstrable endothelial cell differentiation. As well,
Figure 4. Mouse iPSC-derived GFP+ Flt1+/Flt4+ CPCs can be clonally expanded while maintaining phenotype and multipotency. (Aa-
c) Immunofluorescence imaging of live GFP+ Flt1+/Flt4+ single cell CPCs during clonal expansion: (a) single cell post FACS sort, day 1, (b) same colony
on day 14 and (c) on day 30. (Ad-f) CPCs demonstrate trilineage cardiovascular differentiation potential post-clonal expansion. Immunofluorescence
imaging of clonally expanded Flt1+/Flt4+ CPC colonies fourteen days post-differentiation demonstrating (d) TropC-expressing CMs, (e) a-SMA
expressing smooth muscle cells, and (f) CD31 expressing endothelial cells. Cell nuclei are identified with DAPI. (B) FACS analysis thirty days post-clonal
expansion confirms CPCs maintain their Flt1+/Flt4+ CPC phenotype.
doi:10.1371/journal.pone.0045603.g004
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Flt1+/Flt4+ CPCs consistently formed beating colonies and CMs in
vitro, which appeared to be more fetal in phenotype as seen on
immunofluorescence staining (Fig. 4Ad; Figure S2), once trans-
planted in vivo, they formed CMs with a phenotype and
electrophysiological properties typical of adult CMs (Fig. 6). The
reason for this discrepancy is unclear, but external cues from the
local microenvironment play a critical role in determining cell fate
[16] and, a priori, intramyocardial injections would be predicted to
favor cardiomyocyte differentiation. The local extracellular matrix
along with electromechanical stimulation in vivo may play a role in
Figure 5. C57/BL6 iPSC-derived GFP+ Flt1+/Flt4+ CPCs transplanted into strain-matched hearts engraft and robustly differentiate
into CMs and smooth muscle cells. Post-injection immunofluorescence imaging of GFP+ Flt1+/Flt4+ CPCs transplanted into the left ventricle of
C57/BL6 mice demonstrates in vivo engraftment and robust differentiation into CMs and smooth muscle cells. (A & B) Immunostaining of GFP+ Flt1+/
Flt4+ injected myocardial sections for CMs: (a,d) single channels for GFP and (b,e) single channels for TropC with (c,f) merged images. (C)
Immunostaining of GFP+ Flt1+/Flt4+ injected myocardial sections for smooth muscle cells: (g) single channel for GFP and (h) a-SMA along with (i)
merged images.
doi:10.1371/journal.pone.0045603.g005
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evolving CMs to a more mature phenotype. Thus, the ability to
deliver a well-characterized progenitor population derived from
iPSCs capable of integration and robust cardiomyocyte differenti-
ation could be a significant advance for regenerative cardiac cell
therapies.
Both the study and clinical application of the various
cardiovascular progenitor cell types has been limited by their
scarcity and lack of appropriate conditions to expand them in an
undifferentiated state. Progenitor cells are notoriously difficult to
maintain in culture; for example, suitable conditions do not exist to
Figure 6. Transplanted iPSC-derived Flt1+/Flt4+ CPCs differentiate into morphologically and electrophysiologically mature CMs. (A)
10X phase contrast imaging of live, dissociated single CMs post-transplantation of GFP+ Flt1+/Flt4+ CPCs into the LV. (B) Immunofluorescence imaging
of the same field of live cells confirms GFP+ mature CMs derived from transplanted CPCs. (C) 40X image of GFP+ CMs counterstained using DAPI. (D)
FACS analysis of dissociated cells from transplanted hearts demonstrates that ,6% of Troponin I+ CMs are GFP+ labeled using a GFP antibody. (E)
Action potential and (F) fluorescence transient recorded simultaneously from a single GFP+ Flt1+/Flt4+-derived CM loaded with the Ca2+ indicator
rhod-2-AM and paced at 0.2 Hz. (G) Confocal image of live single GFP+ Flt1+/Flt4+-derived CMs post-enzymatic digestion of mouse heart post-
transplant (63X). (H) Live 2D Ca2+ imaging of the same GFP+ CM shown in G which was also loaded with Ca2+ indicator rhod-2-AM. The bright area on
the left shows the beginning of a spontaneous Ca2+ wave. (I) Line scan image from the same CM during depolarization evoked by field stimulation.
The synchronous onset of the Ca2+ transient and rapid increase in fluorescence indicate electrically triggered Ca2+ release. Fluorescence intensities are
displayed in arbitrary units (a.u.) and action potential in millivolt (mV). Scale bars equal 25 mm.
doi:10.1371/journal.pone.0045603.g006
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culture hematopoietic stem cells in vitro despite the fact they were
identified over two decades ago [21]. Here, we describe a novel
approach to expand rare cardiovascular progenitors while
maintaining their trilineage potential in a feeder free manner by
using two small molecules IQ-1, a selective b-catenin inhibitor that
has been shown to maintain pluripotency in ESCs [14], and
Thiazovivn, a ROCK inhibitor, which has been shown to prevent
anoikis and improve survival of single cell ESCs [20]. The use of
IQ-1 differs from other approaches targeted at inhibiting Wnt/b-
catenin signals because instead of globally blocking all Wnt/b-
catenin signals, IQ-1 selectively inhibits the subset of b-catenin
signaling mediated by its interaction with p300, which is pro-
differentiation. We demonstrate that the combination of these
small molecules maintains CPCs in their mutlipotent state and
allows expansion to generate sufficient numbers to allow their
characterization and transplantation in vivo (Fig. 4).
There is increasing awareness that although cell therapy for
ischemic heart disease with adult stem cells may be safe and results in
a modest improvement in ventricular function, current clinical
approaches have largely failed at achieving significant myogenesis
[35]. Any modest effects seen may be transient and secondary to
paracrine effects of transplanted cells rather than true tissue
regeneration. This has resulted in calls for the development of cell
therapy approaches with cell types capable of cardiomyogenic
regeneration, including iPSC-derived cells, which could result in true
myocardial regeneration [4]. While the clinical applicability of early
iPSCs has been questioned because of a potential oncogenic risk
related to the genes used for reprogramming and requirement for
genomic integration, safer more efficient non-viral methods for
reprogramming of human somatic cells have now been described
[36,37]. It is likely that FDA-approvable human iPSCs lines will be
generated in the near future. The use of more differentiated
derivatives should also reduce any risks. However, the relative
efficacy of using CPCs versus more differentiated derivatives such as
iPSC-derived CMs for cell therapy will need to be determined
empirically. Here, we have focused our efforts on iPSC-derived CPCs
because of their potential for more complete regeneration secondary
to their multipotency and possible improved safety profile as
compared to transplanting undifferentiated pluripotent cells such
iPSCs or ECSs. We have shown that mouse iPSC-derived CPCs can
be cloned, which might allow the development of a homogeneous cell
product that could be delivered devoid of any undifferentiated iPSCs
contaminants. Selective manipulation of b-catenin signaling in Flt1+/
Flt4+ CPCs by using the small molecule IQ-1, as well as the use of the
ROCK inhibitor small molecule Thiazovivn, permitted their feeder-
free expansion in vitro, providing for the first time a significant source
of clonally-derived and expanded CPCs, free of feeder cells, for study
in in vivo models. As well, in vivo transplantation demonstrated that
iPSC-derived Flt1+/Flt4+ CPCs have the capacity to engraft into the
native tissue with robust CM differentiation. A recent concern with
iPSC-based regenerative therapies is the possibility of immunogenic-
ity even in immunologically matched iPSCs [38]. The reprogram-
ming process to derive iPSCs, whether it involves retroviral or non-
integrative viral-free approaches to over-express reprogramming
transcription factors, may lead to abnormal expression of tissue-
specific or tumor-specific surface antigens in some iPSC-derived cells
[38]. This in turn can induce a T-cell-dependent immune response
post transplantation of iPSC-derived progenitors, potentially leading
to the destruction of the transplanted iPSCs cells [38]. We did not
observe any immune response generated by transplantation of iPSC-
derived CPCs as we demonstrate robust survival and engraftment of
the iPSC-derived CPCs (Figure S3). This could be related to a
number of factors. At least part of the observed immunological
response previously reported could be related to embryonic antigens
present on the iPSCs, not antigens related to the reprogramming. We
transplanted more differentiated lineage-committed CPCs, which
may be necessary when transplanting into adult tissues. As well, the
pro-survival injection media we used contains the immunosuppres-
sant cyclosporine. Although cyclosporine may not be powerful
enough to suppress the immune response to Human Leukocyte
Antigen (HLA)-mismatched ESCs [39,40,41], it may be sufficient to
overcome any immunological response to iPSC-derived CPCs.
Regardless, the techniques described here will facilitate the study of
iPSC-derived CPCs and potentially the generation of patient-specific
CPC lines, providing a foundation for future clinical application.
Supporting Information
Figure S1 Isl1+ cell staining for the neuronal marker
Map2 and ganglia marker NEFH. (A) Staining of mouse
E15.5 hearts for Microtubule-associated protein 2 (Map2), a pan-
neuronal marker, revealed that most Isl1+ cells in the clusters were
positive for Map2. (B) Staining for Neurofilament, Heavy
Polypeptide (NEFH), a marker of ganglia, demonstrated that
most Isl1+ cells within the core of the cluster were positive for
NEFH. Arrows indicate Isl1+/NEFH2 cells on the periphery of
the cluster. 20X magnification. Cell nuclei are counterstained
using 4’-6-diamidino-2-phenylindole (DAPI) in blue.
(TIF)
Figure S2 Clonally expanded Flt1+/Flt4+ CPCs differ-
entiate into beating colonies with MF-20 (in red) striated
cardiomyocytes seen at 40X. A) 10X, B) 20X, C) 40X. Cell
nuclei are counterstained using 4’-6-diamidino-2-phenylindole
(DAPI) in blue.
(TIF)
Figure S3 Mouse iPSC-derived CPCs do not illicit an
immune response in vivo post transplant. (A) No evidence
of a cellular immune reaction to differentiated iPSC-derived GFP+
CPCs (green) twenty-eight days post transplant into left ventricles
of strain matched hearts in pro-survival media as assayed by
staining for GFP+ cells and CD45+ lymphocytes (red). 10X
magnification. (B) CD45 positive control in a wild type mouse 21
days post infarction of Left Anterior Descending (LAD) artery
reveals infiltration of CD45+ lymphocytes in infarct zone area.
10X magnification. Cell nuclei are counterstained using 4’-6-
diamidino-2-phenylindole (DAPI) in blue.
(TIF)
Methods S1 Supplementary Methods.
(DOC)
Movie S1 Clonally expanded CPCs differentiate into
beating cardiac myocytes.
(MOV)
Table S1 Primary and secondary antibodies.
(DOC)
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